Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

1.

Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro.

Sandee D, Morrissey K, Agrawal V, Tam HK, Kramer MA, Tracy TS, Giacomini KM, Miller WL.

Pharmacogenet Genomics. 2010 Nov;20(11):677-86. doi: 10.1097/FPC.0b013e32833f4f9b.

PMID:
20940534
[PubMed - indexed for MEDLINE]
2.

Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19.

Agrawal V, Huang N, Miller WL.

Pharmacogenet Genomics. 2008 Jul;18(7):569-76. doi: 10.1097/FPC.0b013e32830054ac.

PMID:
18551037
[PubMed - indexed for MEDLINE]
3.

Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3.

Subramanian M, Agrawal V, Sandee D, Tam HK, Miller WL, Tracy TS.

Pharmacogenet Genomics. 2012 Aug;22(8):590-7. doi: 10.1097/FPC.0b013e3283544062.

PMID:
22547083
[PubMed - indexed for MEDLINE]
4.

Consequences of POR mutations and polymorphisms.

Miller WL, Agrawal V, Sandee D, Tee MK, Huang N, Choi JH, Morrissey K, Giacomini KM.

Mol Cell Endocrinol. 2011 Apr 10;336(1-2):174-9. doi: 10.1016/j.mce.2010.10.022. Epub 2010 Nov 9.

PMID:
21070833
[PubMed - indexed for MEDLINE]
5.

Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase.

Agrawal V, Choi JH, Giacomini KM, Miller WL.

Pharmacogenet Genomics. 2010 Oct;20(10):611-8. doi: 10.1097/FPC.0b013e32833e0cb5.

PMID:
20697309
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Genetic variation in human P450 oxidoreductase.

Miller WL, Huang N, Agrawal V, Giacomini KM.

Mol Cell Endocrinol. 2009 Mar 5;300(1-2):180-4. doi: 10.1016/j.mce.2008.09.017. Epub 2008 Sep 26. Review.

PMID:
18930113
[PubMed - indexed for MEDLINE]
7.

Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.

Flück CE, Nicolo C, Pandey AV.

Fundam Clin Pharmacol. 2007 Aug;21(4):399-410. Review.

PMID:
17635179
[PubMed - indexed for MEDLINE]
8.

Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism.

Flück CE, Mullis PE, Pandey AV.

Biochem Biophys Res Commun. 2010 Oct 8;401(1):149-53. doi: 10.1016/j.bbrc.2010.09.035. Epub 2010 Sep 16.

PMID:
20849814
[PubMed - indexed for MEDLINE]
9.

P450 oxidoreductase deficiency: a disorder of steroidogenesis with multiple clinical manifestations.

Miller WL.

Sci Signal. 2012 Oct 23;5(247):pt11. doi: 10.1126/scisignal.2003318. Review.

PMID:
23092891
[PubMed - indexed for MEDLINE]
10.

Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro system.

Moutinho D, Marohnic CC, Panda SP, Rueff J, Masters BS, Kranendonk M.

Drug Metab Dispos. 2012 Apr;40(4):754-60. doi: 10.1124/dmd.111.042820. Epub 2012 Jan 17.

PMID:
22252407
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.

Deeni YY, Paine MJ, Ayrton AD, Clarke SE, Chenery R, Wolf CR.

Arch Biochem Biophys. 2001 Dec 1;396(1):16-24.

PMID:
11716457
[PubMed - indexed for MEDLINE]
12.

Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.

Marcucci KA, Pearce RE, Crespi C, Steimel DT, Leeder JS, Gaedigk A.

Drug Metab Dispos. 2002 May;30(5):595-601.

PMID:
11950793
[PubMed - indexed for MEDLINE]
Free Article
13.

The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency.

Gomes LG, Huang N, Agrawal V, Mendonça BB, Bachega TA, Miller WL.

J Clin Endocrinol Metab. 2008 Jul;93(7):2913-6. doi: 10.1210/jc.2008-0304. Epub 2008 Apr 8.

PMID:
18397975
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

P450 oxidoreductase deficiency: a new disorder of steroidogenesis.

Miller WL, Huang N, Pandey AV, Flück CE, Agrawal V.

Ann N Y Acad Sci. 2005 Dec;1061:100-8. Review.

PMID:
16467261
[PubMed - indexed for MEDLINE]
15.

Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli.

Pritchard MP, Glancey MJ, Blake JA, Gilham DE, Burchell B, Wolf CR, Friedberg T.

Pharmacogenetics. 1998 Feb;8(1):33-42.

PMID:
9511179
[PubMed - indexed for MEDLINE]
16.

Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis.

Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van Vliet G, Sack J, Flück CE, Miller WL.

Am J Hum Genet. 2005 May;76(5):729-49. Epub 2005 Mar 25.

PMID:
15793702
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Biochemical analysis of mutations in P450 oxidoreductase.

Pandey AV.

Biochem Soc Trans. 2006 Dec;34(Pt 6):1186-91.

PMID:
17073782
[PubMed - indexed for MEDLINE]
18.

Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase.

Pandey AV, Kempná P, Hofer G, Mullis PE, Flück CE.

Mol Endocrinol. 2007 Oct;21(10):2579-95. Epub 2007 Jun 26.

PMID:
17595315
[PubMed - indexed for MEDLINE]
19.

Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductase.

Pandey AV, Flück CE, Mullis PE.

Biochem Biophys Res Commun. 2010 Sep 24;400(3):374-8. doi: 10.1016/j.bbrc.2010.08.072. Epub 2010 Aug 21.

PMID:
20732302
[PubMed - indexed for MEDLINE]
20.

CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis.

Subramanian M, Low M, Locuson CW, Tracy TS.

Drug Metab Dispos. 2009 Aug;37(8):1682-9. doi: 10.1124/dmd.109.026500. Epub 2009 May 15.

PMID:
19448135
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk